Liver Function Test (LFT) Procedure, Principle, Result Interpretation, Normal Values and Unit Converter
Definition: A Liver Function Test (LFT) is a group of blood tests used to assess liver health, injury, bile flow, and the liver’s ability to perform important functions.
Purpose: LFTs are performed to detect liver injury or disease, evaluate abnormal liver enzymes, monitor treatment, and assess overall liver function.
| Other Names | Liver Panel, Hepatic Function Panel, Liver Profile |
| Test Technique | Clinical chemistry methods, including spectrophotometry and enzymatic assays |
| Test Type | Blood Test |
| Turnaround time (TAT) | Same day to 1 day |
| Test Cost ($) | $20 – $100 |
| Fasting Required | Usually Not required |
| Medications | Report all prescription, over-the-counter medicines, and supplements; do not stop medication unless instructed. |
| Allowed/Avoid | Follow normal dietary instructions unless the laboratory or healthcare provider advises fasting. |
| Other Preparation | Avoid strenuous exercise and alcohol before testing when specifically advised by the healthcare provider. |
- Required Sample: 3-5 mL Serum or Plasma
- Specimen Container: Serum separator tube (SST) or appropriate chemistry tube
- Alternative Specimen(s): Lithium-heparin plasma may be accepted according to laboratory protocol
- Sample Stability:
• Room Temp (20-25°C): Follow laboratory-specific stability limits
• Refrigerated (2-8°C): Generally preferred for delayed analysis
• Frozen (-20°C and Below): Use only when permitted by the laboratory method - Transport: Prompt transport to the laboratory; protect and refrigerate specimens when required.
- Mislabeling Or Unlabeled sample: Patient identification cannot be verified
- Wrong collection tube: Incorrect tube or additive may affect chemistry results
- Insufficient volume (QNS): Insufficient specimen for the requested panel
- Hemolyzed sample: Significant hemolysis may interfere with selected analytes
- Lipemic / Icteric sample: Severe turbidity or marked icterus may interfere with some assays
- Delayed transport: Excessive delay or improper storage may compromise specimen quality
- Alanine Aminotransferase (ALT)
- Aspartate Aminotransferase (AST)
- Alkaline Phosphatase (ALP)
- Total and Direct Bilirubin
- Albumin and Total Protein
| ALT | Typically about 7 – 56 U/L |
| AST | Typically about 10 – 40 U/L |
| ALP | Typically about 44 – 147 U/L |
| Total Bilirubin | Typically about 0.1 – 1.2 mg/dL |
| Albumin | Typically about 3.5 – 5.0 g/dL |
Quick Facts
Introduction
Definition of the Test
The Liver Function Test (LFT) is a group of clinical chemistry blood tests used to evaluate liver cell injury, bile flow, and the liver’s ability to perform important functions. It measures several biochemical markers, including ALT, AST, and bilirubin, along with proteins and enzymes that help assess overall hepatic health.
Clinical Importance
LFTs are widely used to identify, evaluate, and monitor liver injury, cholestatic disorders, and impaired liver function. The pattern and degree of abnormal results help clinicians determine whether findings are more consistent with hepatocellular injury, cholestasis, or reduced synthetic function.
- Liver Injury: ALT and AST help identify hepatocellular injury.
- Cholestasis: ALP and bilirubin help assess impaired bile flow.
- Synthetic Function: Albumin and related markers provide information about liver protein production.
Role in Modern Laboratory Medicine
Modern clinical laboratories use automated photometric methods, enzymatic assays, and colorimetric techniques to measure LFT components efficiently and consistently. Automated analyzers and laboratory information systems (LIS) support standardized testing, quality control, result verification, and rapid reporting.
Overview of the Test
Specimen: Approximately 3–5 mL of blood collected for serum or plasma testing in an appropriate serum separator or chemistry tube.
Reported Parameters: ALT, AST, ALP, total bilirubin, direct bilirubin, albumin, total protein, and other markers depending on the laboratory’s LFT panel.
Basic Physiology & Scientific Background
The Liver Function Test (LFT) evaluates biochemical markers associated with hepatocellular integrity, bile flow, hepatic metabolism, and the liver’s synthetic capacity. Together, these parameters provide insight into normal liver physiology and patterns of hepatic dysfunction.
Hepatic Physiology
The liver performs essential functions including protein synthesis, nutrient metabolism, detoxification, and bilirubin processing. Measurement of ALT and AST helps assess hepatocellular integrity, while albumin and other proteins reflect aspects of hepatic synthetic function.
Bilirubin Clearance & Excretion
Bilirubin is produced from heme breakdown and transported to the liver for conjugation and subsequent excretion into bile. Disruption of hepatic uptake, conjugation, or biliary excretion can cause bilirubin accumulation and jaundice.
Hepatic & Metabolic Processing
The liver regulates carbohydrate, lipid, protein, and drug metabolism while producing important circulating proteins. Changes in ALT, AST, ALP, GGT, bilirubin, albumin, and total protein may help identify hepatocellular injury, cholestasis, or impaired synthetic function.
Inflammatory & Cellular Response
Hepatic inflammation can alter enzyme release and disturb normal liver function. Conditions such as viral hepatitis, autoimmune liver disease, and inflammatory injury may produce characteristic changes in transaminases and other LFT parameters, helping support clinical assessment.
Protein & Molecular Regulation
Hepatic function depends on coordinated regulation of enzymes, transport proteins, receptors, and plasma proteins. Genetic or acquired abnormalities affecting these pathways may influence bilirubin metabolism, enzyme activity, or protein production and can contribute to abnormal LFT patterns.
Pathological & Clinical Impact
Liver injury, obstruction, infection, alcohol exposure, medications, and metabolic disorders can alter LFT results through different mechanisms. Interpreting the pattern and degree of abnormalities helps distinguish hepatocellular injury from cholestatic or other causes of abnormal liver biochemistry.
LFT Test Components
Alanine Aminotransferase (ALT)
ALT is an enzyme found mainly in hepatocytes and is a sensitive marker of hepatocellular injury.
Aspartate Aminotransferase (AST)
AST is present in the liver and other tissues and may rise with hepatocellular or muscle injury.
Alkaline Phosphatase (ALP)
ALP is associated with bile duct epithelium and bone and is particularly useful when assessing cholestatic patterns.
Total Bilirubin (TBIL)
Total bilirubin represents the combined concentration of unconjugated and conjugated bilirubin in the blood.
Direct Bilirubin (DBIL)
Direct bilirubin primarily reflects conjugated bilirubin that has been processed by hepatocytes and is ready for biliary excretion.
Indirect Bilirubin
Indirect bilirubin is the unconjugated fraction produced mainly from the breakdown of hemoglobin before hepatic processing.
Gamma-Glutamyl Transferase (GGT)
GGT is an enzyme associated with hepatobiliary tissues and can support evaluation of cholestasis and biliary disease.
Albumin (ALB)
Albumin is synthesized by the liver and provides information about hepatic protein production and overall protein status.
Total Protein (TP)
Total protein measures the combined concentration of albumin and globulins and helps assess protein balance and liver synthetic function.
Globulin
Globulins are a group of circulating proteins involved in immune, transport, and other biological functions and may be estimated from total protein and albumin.
Albumin/Globulin Ratio (A/G Ratio)
The A/G ratio compares albumin with globulin concentrations and can provide additional context when interpreting serum protein abnormalities.
Lactate Dehydrogenase (LDH)
LDH is a widely distributed intracellular enzyme that may increase with tissue injury and can provide supportive information in selected liver disorders.
Prothrombin Time (PT)
PT assesses the extrinsic and common coagulation pathways and can help evaluate hepatic synthesis of clotting factors in significant liver dysfunction.
International Normalized Ratio (INR)
INR standardizes prothrombin-time results and is useful for assessing coagulation abnormalities associated with impaired hepatic synthetic function.
Specimen Requirements & Patient Preparation
- Sample Type: Serum or plasma is commonly used for LFT analysis; serum is widely preferred.
- Container: Serum separator tube (SST) or appropriate serum tube; follow the laboratory’s validated collection system.
- Recommended Volume: Usually 2–5 mL of blood is sufficient for a routine LFT panel, depending on analyzer requirements.
- Collection: Collect venous blood using standard phlebotomy technique and allow serum tubes to clot completely before processing.
- Transport Condition: Transport promptly to the laboratory, preferably at controlled room temperature.
- Room Temperature: Keep the separated specimen protected from excessive heat, light, and prolonged delays.
- Refrigeration: If testing is delayed, serum or plasma may generally be stored at 2–8°C according to laboratory-validated stability limits.
- Processing: Allow serum to clot, then centrifuge and separate serum or plasma from cells as soon as practical to minimize preanalytical changes.
- Fasting Status: Fasting is usually not required for routine LFTs unless other tests ordered with the panel require fasting.
- Physical Activity: Avoid strenuous exercise before collection because intense activity may influence AST and other biochemical results.
- Dietary Factors: Avoid unusually heavy or high-fat meals immediately before testing when possible, particularly when other fasting laboratory tests are being performed.
- Medications: Document prescription drugs, over-the-counter medicines, and supplements because some agents can alter ALT, AST, ALP, GGT, or bilirubin results.
- Alcohol Exposure: Record relevant alcohol intake because it may affect several liver-associated biochemical markers, particularly GGT and AST.
- Clinical History: Note known liver disease, recent illness, jaundice, transfusion, or other relevant conditions to support appropriate interpretation of the results.
Principle & Methodology
LFT analysis uses validated clinical chemistry methods to measure liver-associated enzymes, bilirubin, and serum proteins. Understanding the analytical principles helps ensure reliable results and appropriate interpretation of abnormal liver profiles.
Test Principle
LFT parameters are measured using enzyme activity, colorimetric, and spectrophotometric principles. ALT, AST, ALP, and GGT are commonly assessed through enzyme-coupled reactions, while bilirubin is measured through a chemical reaction that produces a measurable color change. Albumin and total protein are quantified using validated photometric methods.
- Enzymatic methods: Measure liver-associated enzyme activity
- Colorimetry: Measures absorbance from colored reaction products
- Spectrophotometry: Quantifies changes in light absorbance
Analytical Methodology
Routine LFT analysis is performed through several standardized analytical stages:
- Specimen preparation — serum or plasma is separated from cellular material
- Reagent reaction — patient sample reacts with assay-specific reagents
- Photometric measurement — absorbance or reaction rate is measured
Quality control: Calibrators and control materials are used to monitor analytical performance before patient results are reported.
Instrumentation
LFT panels are commonly analyzed using automated clinical chemistry analyzers capable of processing multiple biochemical assays from serum or plasma.
- Automated chemistry analyzers — reagent handling and photometric measurement
- Photometric systems — absorbance-based measurement
- Laboratory automation — sample identification and workflow management
Technology Used
Multiple analytical technologies may be combined within an automated LFT platform:
- Enzyme kinetic assays — ALT, AST, ALP, and GGT activity
- Spectrophotometry — absorbance measurement of reaction products
- Bilirubin assays — total and direct bilirubin measurement
- Protein assays — albumin and total protein quantification
- Automation — integrated sample and reagent handling
Test Procedure & Laboratory Workflow
A standardized laboratory workflow helps maintain accuracy, consistency, and traceability throughout LFT testing. Serum or plasma is assessed using validated clinical chemistry methods, followed by quality review and result verification before reporting.
Specimen Receipt
On arrival in the laboratory, the blood specimen is checked before analysis:
- Patient identification — verify identifiers and test request
- Specimen inspection — assess hemolysis, lipemia, volume, and container
- Sample registration — barcode and LIS entry
- Rejection — unsuitable specimens are documented and recollection requested when necessary
Specimen Preparation
Serum or plasma is prepared according to the laboratory’s validated procedure:
- Clotting — allow serum specimens to clot when required
- Centrifugation — separate serum or plasma from blood cells
- Inspection — check for hemolysis, lipemia, and icterus
- Quality control — verify acceptable analyzer and reagent performance
Biochemical Analysis
The prepared specimen is analyzed on a clinical chemistry analyzer:
- Sample aspiration — analyzer introduces the required specimen volume
- Enzyme assays — ALT, AST, ALP, and GGT are measured using validated methods
- Bilirubin testing — total and direct bilirubin are measured separately
- Protein analysis — albumin and total protein are quantified photometrically
Quality Checks
Analytical quality assurance is maintained throughout the testing process:
- Internal QC — control materials monitor daily analytical performance
- Calibration — verify assay calibration according to manufacturer requirements
- Instrument checks — monitor reagents, maintenance, and analyzer status
- Interference review — assess significant hemolysis, lipemia, or icterus flags
Result Validation
Results undergo technical and clinical review before final release:
- Reference interval check — compare results with laboratory ranges
- Flag review — investigate abnormal or instrument-flagged results
- Pattern assessment — consider hepatocellular, cholestatic, or mixed abnormalities
- Critical results — follow laboratory notification procedures when applicable
Reporting
Final LFT results are released with appropriate units, reference intervals, and laboratory comments:
- Electronic report — results transmitted through the LIS
- Interpretive comments — added when clinically or technically appropriate
- Critical notification — urgent results communicated according to policy
- Result archiving — records retained according to applicable laboratory requirements
Comprehensive Liver Function Tests (LFT) Procedure
- Specimen: Serum or Lithium Heparinized Plasma (Fasting 8–12 hrs preferred)
- Centrifugation: 3000 RPM for 10 minutes (Avoid Hemolysis)
- Equipment: Photometer / Auto-Analyzer, Cuvettes (1 cm path), Pipettes
- Sample Stability: Serum stable for 24 hrs at 2–8°C, 2 months at -20°C
| ALT / SGPT (UV Kinetic) | < 45 U/L |
| AST / SGOT (UV Kinetic) | < 35 U/L |
| ALP (p-NPP Kinetic) | 44 – 147 U/L |
| Total Bilirubin (Jendrassik-Grof / DIA) | 0.2 – 1.2 mg/dL |
| Direct Bilirubin (Diazotization) | 0.0 – 0.3 mg/dL |
| Total Protein (Biuret) | 6.0 – 8.3 g/dL |
| Albumin (Bromocresol Green) | 3.5 – 5.2 g/dL |
| Pipelining Step | Blank | Calibrator / Standard | Test Sample |
|---|---|---|---|
| Working Reagent (R1 + R2) | 1000 µL | 1000 µL | 1000 µL |
| Calibrator | — | 100 µL | — |
| Serum / Plasma Sample | — | — | 100 µL |
| ⏱️ INCUBATION: Mix, incubate at 37°C for 1 min. Read Absorbance change per minute (ΔA/min) for 3 minutes. | |||
| Measurement | Set Auto-Zero | Verify Factor | Activity (U/L) |
| Pipelining Step | Total Bili Blank | Total Bili Test | Direct Bili Blank | Direct Bili Test |
|---|---|---|---|---|
| Reagent 1 (Sulfanilic Acid) | 1000 µL | 1000 µL | 1000 µL | 1000 µL |
| Reagent 2 (Sodium Nitrite) | — | 1 drop (50 µL) | — | 1 drop (50 µL) |
| Reagent 3 (Accelerator – Total) | 1000 µL | 1000 µL | — | — |
| Saline (Direct Bili Reaction) | — | — | 1000 µL | 1000 µL |
| Serum / Plasma Sample | 100 µL | 100 µL | 100 µL | 100 µL |
| ⏱️ INCUBATION: Total Bilirubin: 10 min at Room Temp | Direct Bilirubin: Exactly 5 min at Room Temp | ||||
| Measurement | Read Abs Total vs Blank | Read Abs Direct vs Blank | ||
| Pipelining Step | Reagent Blank | Standard | Test Sample |
|---|---|---|---|
| Biuret Reagent (Total Protein) OR BCG Reagent (Albumin) | 1000 µL | 1000 µL | 1000 µL |
| Standard Solution | — | 10 µL | — |
| Serum / Plasma Sample | — | — | 10 µL |
| ⏱️ INCUBATION: Total Protein: 10 min at 37°C | Albumin: 1 min at Room Temp (20–25°C) | |||
| Measurement | Set Auto-Zero | Read Abs Standard | Read Abs Sample |
Note on Blanking: Highly icteric or lipemic samples require a dedicated sample blank to correct for high background absorbance during photometric measurements.
1. Enzyme Kinetic Calculations (ALT, AST, ALP)
Activity (U/L) = ΔA/min × K-Factor
K-Factor = (TV × 1000) / (ε × SV × P)
(TV: Total Vol, SV: Sample Vol, ε: NADH Extinction Coeff = 6.3)
2. End-Point Colorimetric (Total Protein & Albumin)
Conc (g/dL) = (Abs Sample / Abs Standard) × Conc Standard
Standard Conc Albumin = 4.0 g/dL (typical)
3. Bilirubin Calculation (Total & Direct)
Bilirubin (mg/dL) = (Abs Sample – Abs Blank) × Factor
4. Derived Ratios & Protein Fractions
Globulin (g/dL) = Total Protein – Albumin
A/G Ratio = Albumin / Globulin
De Ritis Ratio = AST / ALT
- Run Normal and Pathological controls with each batch
- Monitor Levey-Jennings charts using Westgard rules
- Recalibrate upon reagent lot changes or QC drift
- Hemolysis may affect selected analytes
- Lipemia may interfere with photometric assays
- Medication and specimen factors may affect results
- ALT, AST and ALP patterns
- Bilirubin and GGT results
- Albumin and total protein levels
- Assessment of hepatocellular injury
- Evaluation of cholestatic patterns
- Assessment of hepatic synthetic function
- Hepatocellular Damage: AST/ALT markedly elevated
- Cholestasis / Biliary Obstruction: ALP & Direct Bili elevated
- Chronic Liver Impairment: Low Albumin, reversed A/G ratio
Liver Function Test (LFT) Normal Values Evidence-based reference ranges
| ALT (SGPT) | 7 – 56 U/L 0.12 – 0.95 µkat/L |
| AST (SGOT) | 8 – 48 U/L 0.14 – 0.80 µkat/L |
| ALP | 40 – 129 U/L 0.67 – 2.15 µkat/L |
| Total Bilirubin | 0.1 – 1.2 mg/dL 1.7 – 20.5 µmol/L |
| Direct Bilirubin | 0.0 – 0.3 mg/dL 0.0 – 5.1 µmol/L |
| Albumin | 3.5 – 5.0 g/dL 35 – 50 g/L |
| Total Protein | 6.0 – 8.3 g/dL 60 – 83 g/L |
| GGT | 9 – 48 U/L 0.15 – 0.80 µkat/L |
| Prothrombin Time (PT) | 11.0 – 13.5 sec 11.0 – 13.5 sec |
| ALT (SGPT) | 7 – 55 U/L 0.12 – 0.92 µkat/L |
| AST (SGOT) | 8 – 48 U/L 0.14 – 0.80 µkat/L |
| ALP | 40 – 129 U/L 0.67 – 2.15 µkat/L |
| Total Bilirubin | 0.1 – 1.2 mg/dL 1.7 – 20.5 µmol/L |
| Direct Bilirubin | 0.0 – 0.3 mg/dL 0.0 – 5.1 µmol/L |
| Albumin | 3.5 – 5.0 g/dL 35 – 50 g/L |
| Total Protein | 6.3 – 7.9 g/dL 63 – 79 g/L |
| GGT | 8 – 61 U/L 0.13 – 1.02 µkat/L |
| Prothrombin Time (PT) | 11.0 – 13.5 sec 11.0 – 13.5 sec |
| ALT (SGPT) | 10 – 50 U/L 0.17 – 0.83 µkat/L |
| AST (SGOT) | 10 – 40 U/L 0.17 – 0.67 µkat/L |
| ALP | 30 – 130 U/L 0.50 – 2.17 µkat/L |
| Total Bilirubin | 0.2 – 1.2 mg/dL 3 – 21 µmol/L |
| Direct Bilirubin | 0.0 – 0.3 mg/dL 0.0 – 5.0 µmol/L |
| Albumin | 3.5 – 5.0 g/dL 35 – 50 g/L |
| Total Protein | 6.0 – 8.0 g/dL 60 – 80 g/L |
| GGT | 10 – 60 U/L 0.17 – 1.00 µkat/L |
| Prothrombin Time (PT) | 10.0 – 14.0 sec 10.0 – 14.0 sec |
| ALT (SGPT) | 7 – 56 U/L 0.12 – 0.95 µkat/L |
| AST (SGOT) | 5 – 40 U/L 0.08 – 0.67 µkat/L |
| ALP | 44 – 147 U/L 0.73 – 2.45 µkat/L |
| Total Bilirubin | 0.3 – 1.2 mg/dL 5.1 – 20.5 µmol/L |
| Direct Bilirubin | 0.1 – 0.3 mg/dL 1.7 – 5.1 µmol/L |
| Albumin | 3.4 – 5.4 g/dL 34 – 54 g/L |
| Total Protein | 6.0 – 8.3 g/dL 60 – 83 g/L |
| GGT | 9 – 48 U/L 0.15 – 0.80 µkat/L |
| Prothrombin Time (PT) | 11.0 – 13.5 sec 11.0 – 13.5 sec |
Interpretation of Results: Liver Function Test
LFT interpretation considers bilirubin, aminotransferases, alkaline phosphatase, albumin, and total protein together with symptoms, medical history, and other investigations. Reference intervals vary by laboratory and should always be interpreted using the reported local ranges.
-
↑ ALT / AST: Hepatocellular injury
— commonly associated with viral hepatitis, fatty liver disease, medications, or other hepatic injury.↔ Correlate with: Clinical history, hepatitis markers, ultrasound, and other liver enzymes.
-
↑ ALP + GGT: Cholestatic or biliary involvement
— may occur with bile duct obstruction, cholestasis, or other hepatobiliary disorders.↔ Correlate with: Bilirubin, abdominal imaging, and clinical features of biliary disease.
-
↓ Albumin: Reduced hepatic synthetic function
— may also reflect malnutrition, inflammation, renal protein loss, or other systemic conditions.↔ Correlate with: Total protein, renal assessment, nutritional status, and clinical history.
-
↓ Total Protein: Reduced circulating protein concentration
— may be associated with impaired synthesis, protein loss, or inadequate nutritional intake.↔ Correlate with: Albumin, urine protein assessment, and clinical examination.
- Markedly elevated bilirubin — may indicate significant cholestasis, impaired bilirubin handling, or severe hepatic disease depending on the clinical pattern.
- Severe aminotransferase elevation — may indicate substantial acute hepatocellular injury and requires prompt clinical evaluation.
-
All parameters within range:
Preserved biochemical liver profile
— no significant abnormality is identified by the measured LFT parameters.↔ Correlate with: Symptoms, examination, medications, and clinical history.
-
Isolated mild variation: May be transient or nonspecific
— minor deviations can occur without clinically important liver disease.↔ Correlate with: Previous results and repeat testing when clinically indicated.
📥 Download LFT Test Lab Report Formats
Get the demo report format for Liver Panel in your preferred format. These templates are fully editable and professional.
How to Download?
| File Description | Actions |
|---|---|
Test Report Format (Image) | |
Test Report Format (MS Word) | |
Test Report Format (MS Excel) | |
Test Report Format (PDF) | |
ABC File Download | |
Purchase ABC Book |
Quality Control & Laboratory Considerations
Reliable LFT results depend on careful specimen handling, analytical quality control, and result verification. Monitoring pre-analytical and analytical factors helps minimize errors and improves the clinical reliability of liver chemistry results.
Internal Quality Control (IQC)
Routine QC monitoring confirms that bilirubin, enzyme, and protein assays remain stable and perform within established laboratory limits.
- Control Materials: Run appropriate normal and abnormal levels
- Levey-Jennings Charts: Monitor shifts and trends over time
- Westgard Rules: Identify unacceptable analytical runs
- Mean & SD: Established from laboratory QC data
- CV: Monitor assay precision and analytical variation
- Warning: Investigate control trends or shifts
- Rejection: Do not release patient results until the QC problem is resolved
External Quality Assessment (EQA)
External comparison helps laboratories evaluate LFT analytical performance against peer laboratories or assigned target values.
- Bilirubin Testing: Assessment of total and direct bilirubin performance
- Enzyme Assays: ALT, AST, ALP, and GGT comparison
- Protein Testing: Albumin and total protein performance
- Frequency: According to the laboratory’s EQA schedule
- Comparison: Results evaluated against assigned targets
- Acceptable: Performance within the program’s limits
- Unacceptable: Investigate causes and document corrective action
Calibration
Proper calibration links the analyzer’s analytical signal to the assigned concentration of each LFT analyte.
- Calibrators: Use manufacturer-specified materials
- Analytes: Bilirubin, ALT, AST, ALP, GGT, albumin, and other reported assays
- Frequency: Follow manufacturer and laboratory requirements
- Calibration Verification — confirm expected analytical response across the measuring range
- Acceptance: Calibration meets predefined criteria
- Recalibration: Perform when required by assay or manufacturer
- Drift: Investigate persistent shifts in QC performance
LFT Method Validation
Method verification and validation confirm that each chemistry assay performs appropriately for its intended clinical use.
- Precision: Assess repeatability and reproducibility
- Accuracy: Compare results with appropriate reference or established methods
- Analytical Measurement Range: Confirm reportable limits
- Interference: Evaluate relevant effects such as hemolysis, lipemia, and icterus
- Reference Intervals: Verify locally applicable intervals
- Patient Correlation: Compare results with clinical expectations
- Documentation: Record acceptance criteria and verification results
Analyzer & Laboratory Maintenance
Preventive maintenance and routine checks help maintain stable analyzer performance and reduce avoidable analytical errors in LFT testing.
- Startup: Check analyzer status, reagents, and system background
- Reagents: Verify levels, expiry dates, and storage conditions
- QC: Review control results before patient reporting
- Cleaning: Maintain probes, cuvettes, tubing, and reaction areas
- Inspection: Check reagent lines and fluidic components
- Performance: Monitor carryover, drift, and recurring error flags
- Calibration: Perform according to assay requirements
- Preventive Maintenance: Follow manufacturer service schedules
- Documentation: Record maintenance, faults, and corrective actions
LFT Correlation Matrix
Liver Enzymes + Hepatocellular Injury
LFT + Cholestatic Pattern
LFT + Bilirubin Correlation
LFT + Liver Synthetic Function
LFT + GGT / ALP Differentiation
LFT + Renal & Systemic Correlation
Frequently Asked Questions
Common questions from patients, students, and healthcare professionals. Click on any question to expand the answer.
This test is ordered for routine health screening, diagnosing specific conditions, or monitoring treatment response. Your healthcare provider may order it if you have symptoms such as fatigue, unexplained weight changes, fever, or abnormal physical examination findings. It is also used for preoperative evaluation and chronic disease management.
Fasting requirements depend on the specific test. For many basic tests, fasting is not required. However, if your test includes lipid panel, glucose, or iron studies, you may need to fast for 8–12 hours. Always follow your healthcare provider’s instructions. Water is usually allowed. See our patient preparation guide for detailed information.
Turnaround time varies by test type and laboratory workflow. Routine tests typically take 2–24 hours. STAT/urgent tests are processed in 1–2 hours. Complex or specialized tests may take several days. Your healthcare provider will inform you when to expect results and schedule a follow-up appointment for interpretation.
This test is generally safe with minimal risks. Common minor risks include bruising, bleeding, or lightheadedness at the collection site. Serious complications are rare. Inform your phlebotomist if you have a history of bleeding disorders, are taking anticoagulants, or have anxiety about needles. Safety protocols are strictly followed.
Abnormal results indicate potential pathology and require clinical correlation. High levels may suggest polycythemia, infection, or malignancy. Low levels may indicate anemia, bone marrow suppression, or deficiency. The clinical significance of each parameter must be interpreted in context of patient history, physical examination, and other laboratory findings. Disease associations provide diagnostic clues.
Pre-analytical errors account for 60–70% of laboratory errors. Common causes include:
- Hemolysis — traumatic draw, improper mixing, prolonged tourniquet
- Lipemia — non-fasting sample, high-fat meal
- Clotted sample — insufficient mixing, delayed processing
- Inadequate volume — EDTA dilution, platelet clumping
- Delayed transport — cellular metabolism alters analytes
See pre-analytical errors guide for comprehensive information.
Modern laboratories use multiple integrated technologies:
- Flow cytometry — cell enumeration, differential, immunophenotyping
- Impedance (Coulter principle) — cell counting and sizing
- Spectrophotometry — hemoglobin measurement
- Fluorescence — reticulocytes, immature platelets, blasts
- Laser scatter — cell granularity and complexity
- AI morphology — digital image analysis, flagging
Learn more at methodology overview and instrumentation guide.
Reference ranges are population-specific and vary by age, sex, ethnicity, and geographic location. They represent the central 95% of healthy individuals. Values outside the reference range do not always indicate disease — they may be normal for you or require clinical correlation. Laboratories establish their own reference intervals based on local populations. Always use the age-appropriate and sex-appropriate ranges provided on your report.
Critical values represent life-threatening results requiring immediate action. Thresholds vary by institution but typical examples include:
- Hemoglobin: ≤ 5.0 g/dL or ≥ 20.0 g/dL
- Platelets: ≤ 20 × 10³/µL or ≥ 1,000 × 10³/µL
- WBC: ≤ 1.0 × 10³/µL or ≥ 50.0 × 10³/µL
- Potassium: ≤ 2.5 mmol/L or ≥ 6.5 mmol/L
- Glucose: ≤ 40 mg/dL or ≥ 500 mg/dL
See critical values protocol for complete guidelines and notification requirements.
Comprehensive quality control includes:
- Internal QC (IQC): Daily 3-level controls, Levey-Jennings charting, Westgard multirules
- External QC (EQA): CAP/UK NEQAS proficiency testing (3–4 times/year)
- Calibration: Certified reference materials, lot-specific adjustments
- Validation: CLSI EP guidelines, 40+ patient sample correlation, reference interval verification
- Maintenance: Daily, monthly, and annual preventive maintenance schedules
Follow quality control guidelines and ISO 15189 standards.
Special populations require adjusted approaches:
- Pregnancy: Physiologically adjusted ranges; routine iron/folate supplementation
- Pediatrics: Age-specific reference intervals; minimized blood volume; developmentally appropriate phlebotomy
- Elderly: Multifactorial anemia; polypharmacy considerations; gentle phlebotomy technique
- Immunocompromised: Infection risk mitigation; individualized transfusion thresholds; growth factor support
Refer to special considerations guide for detailed protocols.
Interfering substances can cause inaccurate results:
- Hemolysis: Interferes with K, LDH, bilirubin, immunoassays
- Lipemia: Affects Hgb, bilirubin, turbidimetric assays
- Biotin: Interferes with streptavidin-based immunoassays
- Medications: Heparin (↓ platelets), steroids (↑ WBC), chemotherapy (cytopenias)
- Heterophile antibodies: False positive/negative in immunoassays
See interference guide for complete list and management.
